FDA Approvals | mAb

Products regulated by the Food and Drug Administration comprise 25% of American consumer spending. The approaches used to approve these products can be as varied and complex as the products themselves. Such differences are dictated by Federal law and FDA identifies and enforces the relative risks and benefits that the products pose to consumers. These results convey summaries of products approved by FDA, including information about their past history and present status. The information not only applies to New Molecular Entities, but includes FDA approval information pertaining to new ingredients, dosages, therapeutic uses and generic equivalents.

Top 5 innovator ingredients

Top 5 generic ingredients

Top 5 innovator sponsors

Top 5 generic sponsors

Note: these approvals are sourced from Drugs@FDA and Purple Book, and do not currently reflect older FDA approvals and/or other evidence of US marketing.

Active Ingredients

Active IngredientInnovator SponsorApproval YearsInnovator YearsInnovatorGenericType
clobetasolFougera1985 - 20251985 - 20241387mAb
muromonab cd3Centocor1992199210mAb
abciximabJohnson and Johnson1994199410mAb
capromab pendetideAYTU BioScience1996199610mAb
imciromab pentetateCentocor1996199610mAb
daclizumabRoche1997 - 20161997 - 201620mAb
rituximabGenentech1997 - 20201997 - 202060mAb
basiliximabNovartis1998199810mAb
infliximabJohnson and Johnson1998 - 20231998 - 202360mAb
palivizumabSwedish Orphan Biovitrum1998199810mAb
TC99M nofetumomab merpentanBoehringer Ingelheim1998199810mAb
trastuzumabGenentech1998 - 20241998 - 202490mAb
gemtuzumab ozogamicinAmerican Home Products2000 - 20172000 - 201720mAb
alemtuzumabGenzyme2001200110mAb
adalimumabAbbVie2002 - 20242002 - 2024110mAb
ibritumomab tiuxetanAcrotech Biopharma LLC2002200210mAb
efalizumabGenentech2003200310mAb
omalizumabGenentech2003 - 20252003 - 202520mAb
tositumomabGlaxoSmithKline2003200310mAb
bevacizumabGenentech2004 - 20252004 - 202570mAb
159 ingredients
Page 1 / 8

Approval Applications

Appl NoTypeApprovalSponsorActive IngredientsMarketing StatusClassPriority?Links

Submission class glossary

TYPE 1
New Molecular Entity
TYPE 2
New Active Ingredient
TYPE 3
New Dosage Form
TYPE 4
New Combination
TYPE 5
New Formulation or New Manufacturer
TYPE 6
New Indication (pre-2009)
TYPE 7
Drug Already Marketed without Approved NDA
TYPE 8
Partial Rx to OTC Switch
TYPE 9
New Indication or Claim (existing NDA)
TYPE 10
New Indication or Claim (additional NDA)
MEDGAS
Medical Gas